ArticleFrontiers in pharmacology2013
Eosinophilic inflammation in allergic asthma.
Article in Frontiers in pharmacology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 89 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
89 citing papers in PubMed, 1 synthesis or guideline pooled it, 197 citations in OpenAlex.
- Mepolizumab in the treatment of eosinophilic chronic obstructive pulmonary disease.International journal of chronic obstructive pulmonary disease · 2019Pooled it
- Eosinophils enhance WNT-5a and TGF-β1 genes expression in airway smooth muscle cells and promote their proliferation by increased extracellular matrix proteins production in asthma.BMC pulmonary medicine · 2016Trial
- Establishment of a novel murine model of allergic bronchopulmonary aspergillosis using an eosinophilic mutant mouse.The Journal of veterinary medical science · 2026Article
- Risk Factors and Mechanisms Leading to Preschool Recurrent Wheeze and Asthma.The journal of allergy and clinical immunology. In practice · 2025Review
- METRNL mitigates oxidative stress and inflammatory drawbacks in ovalbumin/lipopolysaccharide-induced allergic airway diseases via the IKK/IκB/NF-κB signaling pathway.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- BRL-50481 Ameliorates Lung Inflammation in a Murine Model of Ovalbumin-Induced Allergic Asthma with Co-Exposure to Lipopolysaccharide.Biomolecules & therapeutics · 2025Article
- Targeting carboxypeptidase A/B activity with the phosphinic inhibitor C28 reduces the asthmatic response in a mouse model of house dust mite-induced asthma.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2025Article
- EndoPRS: Incorporating endophenotype information to improve polygenic risk scores for clinical endpoints-A study in asthma.American journal of human genetics · 2025Article
- Lipid mediators obtained from docosahexaenoic acid by soybean lipoxygenase alleviate ovalbumin‑induced allergic asthma in mice by reducing airway inflammation and oxidative stress.Molecular medicine reports · 2025Article
- Biologics and airway remodeling in asthma: early, late, and potential preventive effects.Allergy · 2025Review
- Advances in pulmonary neuroendocrine cells and their cellular interactions in asthma pathogenesis.Frontiers in pharmacology · 2025Review
- Integrative Cross-Talk in Asthma: Unraveling the Complex Interactions Between Eosinophils, Immune, and Structural Cells in the Airway Microenvironment.Diagnostics (Basel, Switzerland) · 2024Review
- A Review on Asthma and Allergy: Current Understanding on Molecular Perspectives.Journal of clinical medicine · 2024Review
- Vinpocetine, a phosphodiesterase 1 inhibitor, mitigates atopic dermatitis-like skin inflammation.The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2024Article
- Immunoregulatory role of hesperidin against ovalbumin (OVA)-induced bronchial asthma and depression in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Different bacterial cargo in apoptotic cells drive distinct macrophage phenotypes.Apoptosis : an international journal on programmed cell death · 2024Article
- The airway epithelium: an orchestrator of inflammation, a key structural barrier and a therapeutic target in severe asthma.The European respiratory journal · 2024Review
- Airway remodelling in asthma and the epithelium: on the edge of a new era.The European respiratory journal · 2024Review
- Article
- Eosinophils and Cognitive Impairment in Schizophrenia: A New Perspective.Journal of blood medicine · 2024Review
29 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Eosinophils are circulating granulocytes involved in pathogenesis of asthma. A cascade of processes directed by Th2 cytokine producing T-cells influence the recruitment of eosinophils into the lungs. Furthermore, multiple elements including interleukin (IL)-5, IL-13, chemoattractants such as eotaxin, Clara cells, and CC chemokine receptor (CCR)3 are already directly involved in recruiting eosinophils to the lung during allergic inflammation. Once recruited, eosinophils participate in the modulation of immune response, induction of airway hyperresponsiveness and remodeling, characteristic features of asthma. Various types of promising treatments for reducing asthmatic response are related to reduction in eosinophil counts both in human and experimental models of pulmonary allergic inflammation, showing that the recruitment of these cells really plays an important role in the pathophysiology of allergic diseases such asthma.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.